Posts by: Margarida Azevedo

Margarida Azevedo

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

March 21, 2016March 21, 2016

BPH Animal Model Shows Medicinal Plant Extract Prevents Abnormal Cell Production, Has Antioxidant Effects

News

Researchers at Iran’s Zahedan University of Medical Sciences investigated the inhibitory effects of the medicinal plant Withania coagulans extract (WCE) in rats with induced benign prostate hyperplasia (BPH), finding the plant inhibits ... Read more

March 15, 2016March 15, 2016

UroLift System for LUTS Given Highest Possible Rating in Updated EAU Guidelines

News

The European Association of Urology (EAU) has raised the rating of the UroLift system to the highest possible classification, Level 1A, in its recently updated guidelines for male lower urinary tract symptoms ... Read more

March 4, 2016March 4, 2016

LUTS Treatment in Newly Diagnosed BPH Patients Follows Care Standards with One Odd Glitch, Study Reports

News

Researchers examining diagnostic tests and treatment patterns from a large database of newly diagnosed benign prostatic hyperplasia (BPH) patients observed that the clinical care provided these patients largely followed guideline ... Read more

February 24, 2016February 24, 2016

Testing PSA Levels Is Very Important, Especially as Men Age

News

Prostate-specific antigen (PSA), a protein produced by the prostate gland, is often regarded as an indicator of prostate health. But elevated PSA levels can arise from different causes and are not ... Read more

January 18, 2016January 18, 2016

BPH Protein Complex Linked to Potential Treatment Resistance

News

Researchers studying the molecular effects of activating a protein complex that controls vital cellular activities — in this case, inflammation — linked it for a first time to an increase in the androgen receptor ... Read more

January 6, 2016January 6, 2016

IMBiotechnologies Treats First Patient in Enlarged Prostate Study of OCL 500 Embolization Safety and Efficacy

News

IMBiotechnologies Ltd. has announced the treatment of the first patient in its clinical study to evaluate the safety and efficacy of OCL500, an agent for prostate artery embolization to treat benign prostate hypertrophy (BPH). Dr. ... Read more

January 5, 2016January 5, 2016

2 TURP Surgical Approaches for BPH Both Found Safe, Effective

News

Pre- and post-operative clinical parameters and outcomes in benign prostatic hyperplasia (BPH) patients who underwent either monopolar or bipolar transurethral resection of the prostate (TURP) were compared in a recent study titled “Safety ... Read more

December 2, 2015

NxThera Publishes Rezum II Clinical Study Results on BPH Symptoms

News

NxThera, Inc., a therapeutic device company responsible for the development of the Convective Water Vapor Energy (WAVE) technology platform for the treatment of Benign Prostatic Hyperplasia (BPH), has published the results ... Read more

November 30, 2015November 30, 2015

New Therapeutic Thermobalancing Device Relieves BPH Symptoms

News

A new study reports on the efficacy of thermobalancing therapy using a new therapeutic device in the treatment of patients with benign prostatic hyperplasia (BPH). The results indicate the novel therapy ... Read more

November 9, 2015November 11, 2015

BPH Drug Seen to Reduce Post-Surgery Blood Loss in Patients

News

Researchers at the Hanyang University College of Medicine in Seoul have conducted a study indicating that treatment with dutasteride prior to transurethral resection of the prostate reduces bleeding and hospitalization ... Read more